Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.
Alterome Therapeutics has raised $132.0M in total funding. The most recent round was Series B. The last funding was announced in April 2024.
Alterome Therapeutics's investors include Blue Owl, Goldman Sachs, OrbiMed, Vida Ventures, Canaan Partners.
Alterome Therapeutics is headquartered in San Diego, United States.
Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.
Alterome Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alterome Therapeutics — Funding & Investors." VCBacked, April 3, 2024, https://www.vcbacked.co/company/alterome-therapeutics. Accessed July 28, 2026.
VCBacked. (2024). Alterome Therapeutics — Funding & Investors. Retrieved July 28, 2026, from https://www.vcbacked.co/company/alterome-therapeutics
{{cite web |title=Alterome Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alterome-therapeutics |website=VCBacked |access-date=July 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated